Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Universitätsklinik für Innere Medizin
Klinische Abteilung für Onkologie
SCI/PUBMED gelistet | alle Publikationstypen | Gesamt nach Jahr und Erstautor | MUG-Autor*innen |
** = Publikationen gelistet in SCI/SSCI/Pubmed
Originalarbeit (Zeitschrift)
** Agrawal, D; Cisarova, K; Vosberg, S; Allmendinger, F; Munkhbaatar, E; Dandachi, N; Fernandez, Hernandez, FJ; Tonietto, M; Jäger, V; Anton, M; Keller, EC; Jesinghaus, M; Meinhardt, AL; Haefner, V; Stoeger, T; Steiger, K; McGranahan, N; Dengler, MA; Wahida, A; Jost, PJ
Aberrant methylation limits antitumoral inflammation in lung adenocarcinoma by restricting RIPK3 expression.
Sci Adv. 2026; 12(4):eadz9227
Doi: 10.1126/sciadv.adz9227
PubMed
FullText
FullText_MUG
** Jahn, S; Krajina, K; Smolle, MA; Neufeldt, D; Jonas, K; Rinner, B; Mellert, K; Noeparast, M; Trepel, M; Szkandera, J; Pichler, M; Liegl-Azwanger, B
Clinical Significance and Therapeutic Potential of Long Non-Coding RNA H19 in Soft Tissue Sarcoma.
Cancer Med. 2026; 15(1):e71305
Doi: 10.1002/cam4.71305
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Singer, CF; Koenig, F; Kacerovsky-Strobl, S; Danzinger, S; Brunner, C; Suppan, C; Deutschmann, C; Balic, M; Greil, R; Egle, D; de, Azambuja, E; Di, Cosimo, S; Choudhury, A; Gnant, M
HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trial.
Breast. 2025; 85:104679
Doi: 10.1016/j.breast.2025.104679
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Vejzovic, D; Karner, C; Fechter, K; Ritter, G; Holzer, V; Barones, L; Schweintzger, NA; Wagner, K; Lyssy, F; Gauster, M; Szkandera, J; Stanzer, S; Prietl, B; El-Heliebi, A; Lohberger, B; Guillén-Navaro, MJ; Avilés, PM; Brčić, I; Liegl-Atzwanger, B; Rinner, B
Drug screening reveals differential drug response in primary and metastatic clear cell sarcoma.
Cancer Lett. 2025; 218131
Doi: 10.1016/j.canlet.2025.218131
Web of Science
PubMed
FullText
FullText_MUG
** Vlachos, G; Moser, T; Lazzeri, I; Moser, MJ; Glawitch, L; Bauernhofer, ET; Eberhard, A; Beichler, C; Sadeghi, H; Blatterer, J; Kühberger, S; Monsberger, N; Terbuch, A; Kashofer, K; Geigl, JB; Bauernhofer, T; Heitzer, E
Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility.
Br J Cancer. 2026;
Doi: 10.1038/s41416-025-03301-0
Web of Science
PubMed
FullText
FullText_MUG
** Zurl, H; Embacher, S; Schöllnast, H; Talakic, E; Schöpfer-Schwab, S; Pohl, K; Scheipner, L; Jasarevic, S; Altziebler, J; Mangge, A; Mannweiler, S; Riedl, J; Bele, U; Leitsmann, C; Leitsmann, M; Hutterer, G; Ahyai, S; Mischinger, J
MRI prostate tumor volume predicts the need for systematic biopsies in patients undergoing MRI-targeted biopsy.
Minerva Urol Nephrol. 2026;
Doi: 10.23736/S2724-6051.25.06375-X
PubMed
FullText
FullText_MUG
Übersichtsarbeit
** Berton, F; Rinnerthaler, G
Efficacy of sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, in metastatic triple-negative breast cancer
MEMO-MAG EUR MED ONC. 2026;
Doi: 10.1007/s12254-025-01101-z
Web of Science
FullText
FullText_MUG
** Edlinger, L; Egger, V; Riedl, JM
Bridging the gap: targeted treatment strategies for cancer of unknown primary
MEMO-MAG EUR MED ONC. 2026;
Doi: 10.1007/s12254-025-01099-4
Web of Science
FullText
FullText_MUG